Revolutionizing CLL Treatment with Cutting-Edge Biotechnology
| Innovative Biotechnology for a Healthier Future
SinABiomedics GmbH is pioneering advanced biotechnology solutions to fight chronic lymphocytic leukemia (CLL). Learn more about our groundbreaking research and development efforts. Join us on the forefront of medical innovation as we pioneer advanced solutions for CLL. Discover our groundbreaking research guiding us to a novel Biomarker for high risk CLL and opens the way for reliable diagnostics followed by tumor specific treatment.
RESEARCH & HISTORY
| Biomarker R110 – Articles and Publication
Explore the journey of our breakthrough IGLV3-21R110 (R110) research. Learn about the novel biomarker R110 for high risk CLL and explore the rising need for including R110 in CLL clinical routine.
Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia
Minici, C., Gounari, M., Übelhart, R. et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun 8, 15746 (2017).
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
Maity PC, et.al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327. doi: 10.1073/pnas.1913810117. Epub 2020 Feb 11. PMID: 32047037; PMCID: PMC7049113.
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Charlotte Syrykh, et al. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Adv 2023; 7 (23): 7384–7391. doi: https://doi.org/10.1182/ bloodadvances.2023010132
IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial
Deyan Y. Yosifov et al. Blood (2023) 142 (Supplement 1): 1903. https://doi.org/10.1182/blood-2023-179767
Time to include IGLV3-21R110 status in CLL prognostication?
Richard Rosenquist, Blood Adv (2023) 7 (23): 7382–7383. https://doi.org/10.1182/bloodadvances. 2023011243
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
Märkl, F., Schultheiß, C., Ali, M. et al. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. Nat Commun 15, 993 (2024). https://doi.org/10.1038/s41467-024-45378-w
THE SCIENCE
BEHIND CLL
CAPABILITIES
| What Our Antibody Can Do
Discover the unique capabilities of our monoclonal antibody for R110 detection in flow cytometry. Learn about the advantages of our approach compared to traditional sequencing. Currently we are establishing a R110-User Group for exchange experience. We keep you updated about the next steps to come. If you want to become part of it, just check the box on your quotation form below.
In addition to diagnostics, we are currently developing a treatment concept targeting the R110 biomarker. This approach promises, for the first time, tumor-specific treatment in CLL and a maximum reduction in the risk of immunodeficiencies and secondary infections. We will keep you informed about our progress…
| How the antibodies work
Biomarker IGLV3-21R110 (R110) At a Glance
SIN-A-1001 – Precise stratification via flow cytometry
HOW TO ORDER?
| Get Your Quotation Now!
Right now, Anti-R110 is available in APC and PE. Each tube contains antibodies for 10 tests.
Additional fluorochromes will be available in the near future.
For getting your quotation to order anti-R110 antibody for flow cytometry application you have just to fill this form.
Your request will be processed as quickly as possible by our partner MabTech GmbH, who will then send you your quote.